Regencell Bioscience Holdings shares rose over 20% premarket, extending a sharp rally that has lifted the stock nearly 152% in early 2026 and about 218% since late October. The surge comes despite the company warning of substantial doubt about its ability to continue as a going concern and reporting ongoing losses.